A fundamental analysis of Gufic Biosciences (GUFICBIO) covering revenue trends, profitability, valuation, and shareholding patterns.
Gufic Biosciences Revenue Trend
In FY2025, Gufic Biosciences posted revenue of ₹820 Cr, up 1.4% from ₹809 Cr a year earlier.
Revenue has compounded at 18.4% per year over the past 10 years, from ₹152 Cr to ₹820 Cr. This is robust top-line growth by any measure.
With a top line of ₹820 Cr, Gufic Biosciences operates at a smaller scale within the pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹820 Cr | +1.4% |
| FY2024 | ₹809 Cr | +16.7% |
| FY2023 | ₹693 Cr | -11.4% |
| FY2022 | ₹782 Cr | +59.2% |
| FY2021 | ₹491 Cr | — |
View Gufic Biosciences's full 10-year revenue trend with CAGR analysis →
Gufic Biosciences Profitability
Net income for Gufic Biosciences weakened to ₹69.6 Cr in FY2025, 19.1% lower than the ₹86.1 Cr posted in FY2024.
The net margin narrowed from 10.6% to 8.5%, suggesting rising cost pressures.
Diluted EPS stood at ₹6.95 in FY2025, compared to ₹8.74 in FY2024.
Is Gufic Biosciences Undervalued
Under the P/E Ratio approach, Gufic Biosciences's estimated fair value is ₹285 (21.4% downside).
Gufic Biosciences shares are currently trading at ₹361.95.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹285 | 21.4% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Gufic Biosciences with detailed assumptions →
Gufic Biosciences Shareholding Pattern
No change in promoter stake — it has held at 72.5% for the past 4 quarters.
The FII stake is at 0.4% as of March 2026, compared to 0.3% in the year-ago period.
Domestic institutions moved their stake up to 3.8% from 3.4% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 72.5% | 0.4% | 3.8% | 23.2% |
| Dec 2025 | 72.5% | 0.4% | 3.7% | 23.3% |
| Sep 2025 | 72.5% | 0.3% | 3.6% | 23.5% |
| Jun 2025 | 72.5% | 0.3% | 3.4% | 23.8% |
Track quarterly shareholding changes for Gufic Biosciences →
Gufic Biosciences Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹11.69B, up 7.0% YoY from ₹10.93B.
Property, Plant & Equipment accounts for 42.5% of the total, ahead of Receivables (26.9%) and Inventories (18.5%).
Capital structure: 51.4% equity, 28.8% debt, 19.8% operating liabilities. Over the year, debt is up 1.0% and equity is up 12.9%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 157.23M |
| Receivables | 3.15B |
| Inventories | 2.17B |
| Property, Plant & Equipment | 4.97B |
| Investments | 17.84M |
| Intangibles & Goodwill | 63.44M |
| Other Assets | 1.17B |
| Category | Value |
|---|---|
| Equity | 6.01B |
| Short-term Debt | 1.86B |
| Long-term Debt | 1.50B |
| Trade Payables | 1.59B |
| Other Liabilities | 733.43M |
Gufic Biosciences — The Bottom Line
What should investors take away from Gufic Biosciences's (GUFICBIO) latest numbers? Here's the summary.
Revenue of ₹820 Cr in FY2025, up 1.4% year-over-year.
Long-term revenue has been compounding at 18.4% annually over 10 years.
The company is profitable, with a net margin of 8.5% and net income of ₹69.6 Cr.
The P/E Ratio model implies 21.4% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Gufic Biosciences's detailed profile on Craytheon.